Literature DB >> 30550528

NEW PROPOSAL FOR THE PATHOPHYSIOLOGY OF TYPE 3 NEOVASCULARIZATION AS BASED ON MULTIMODAL IMAGING FINDINGS.

Richard F Spaide1.   

Abstract

PURPOSE: To investigate the imaging characteristics of early Type 3 neovascularization and propose a new pathophysiologic sequence for early disease.
METHODS: Patients were evaluated with a comprehensive ophthalmologic examination to include fundus photography, optical coherence tomography, optical coherence tomography angiography, fluorescein angiography, and volume-rendered optical coherence tomography angiography. Relevant literature was also reviewed.
RESULTS: There were 10 eyes of 9 patients who had a mean age of 87 (range 79-93) years and 7 were women. The patients were seen to have distributed areas of cystoid macular edema, not necessarily contiguous with areas of fluorescein or optical coherence tomography angiographic evidence of neovascularization, which colocalized with each other. Areas of hemorrhage were not necessarily contiguous with observed neovascularization. In some patients, massive amounts of edema were imaged, although the associated neovascular invasion was small and did not reach deeper portions of the retina. These findings were readily responsive to intravitreal injections of anti-vascular endothelial growth factor (VEGF) medication. Review of published literature showed conflicting pathophysiologic proposals, which did not abide with contemporaneous imaging findings.
CONCLUSION: Type 3 neovascularization likely grows in response to increased cytokine levels, particularly VEGF, in a permissive environment. Elevated levels of VEGF have been shown to cause hemorrhage, edema, and telangiectasis in the macula, suggesting some of the manifestations of Type 3 neovascularization are related to increased tissue VEGF levels and not necessarily to the neovascularization alone. A proposal based on imaging and histopathologic findings and known physiologic effects of VEGF is presented.

Entities:  

Year:  2019        PMID: 30550528     DOI: 10.1097/IAE.0000000000002412

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

1.  Assessing the long-term evolution of type 3 neovascularization in age-related macular degeneration using optical coherence tomography angiography.

Authors:  Han Joo Cho; Soo Hyun Lim; Jaemin Kim; Jihyun Lee; Dong Won Lee; Jong Woo Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-21       Impact factor: 3.117

2.  Clinical features associated with the atrophy of fellow eyes in patients with unilateral type 3 macular neovascularization.

Authors:  Mihyun Choi; Eun Gyu Yoon; Ki Tae Nam; Cheolmin Yun
Journal:  Int Ophthalmol       Date:  2022-09-04       Impact factor: 2.029

3.  Chorioretinal thickness and retinal pigment epithelial degeneration of fellow eyes in patients with unilateral neovascular age-related macular degeneration with subretinal drusenoid deposits.

Authors:  Dongwan Kang; Eun Gyu Yoon; Ki Tae Nam; Cheolmin Yun
Journal:  BMC Ophthalmol       Date:  2022-07-14       Impact factor: 2.086

4.  The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3.

Authors:  Bilal Haj Najeeb; Gabor G Deak; Ursula Schmidt-Erfurth; Bianca S Gerendas
Journal:  Acta Ophthalmol       Date:  2021-04-05       Impact factor: 3.988

5.  Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization.

Authors:  Wontae Yoon; Jihyun Yoon; Seung Kwan Na; Jihyun Lee; Jaemin Kim; Jong Woo Kim; Han Joo Cho
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

6.  The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration.

Authors:  Emily S Levine; Eugenia Custo Greig; Luísa S M Mendonça; Shilpa Gulati; Ivana N Despotovic; A Yasin Alibhai; Eric Moult; Nora Muakkassa; Maddalena Quaranta-El Maftouhi; Adil El Maftouhi; Usha Chakravarthy; James G Fujimoto; Caroline R Baumal; Andre J Witkin; Jay S Duker; M Elizabeth Hartnett; Nadia K Waheed
Journal:  Int J Retina Vitreous       Date:  2020-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.